Dr. Mark Hyman Longevity Protocol: A Clinical Interpretation

Who Is Dr. Mark Hyman and Why Does His Protocol Matter?

Dr. Mark Hyman is a practicing family physician, a 15-time New York Times bestselling author, and a former senior advisor at the Cleveland Clinic Center for Functional Medicine. He has spent roughly three decades applying functional medicine principles to what he calls "treating the root cause" rather than managing symptoms. His 2023 book "Young Forever" and his podcast "The Doctor's Farmacy" are the primary public records of his disclosed protocol.

His influence is not trivial. The Doctor's Farmacy podcast regularly ranks in the top 50 US health podcasts, and his statements reach millions of listeners who may act on his recommendations. That reach makes clinical scrutiny appropriate.

Why This Clinical Review Exists

Hyman occupies an unusual position: he holds a medical license, teaches at academic institutions, and simultaneously promotes a supplement regimen that far exceeds standard clinical guidelines. Separating what the evidence supports from what represents personal experimentation is the purpose of this article.

All practices described here are drawn from his publicly available interviews, podcast episodes, and books. Where a specific dose or product is inferred from context rather than explicitly stated, that is labeled [INFERENCE] inline.

Hormone Therapy: Testosterone, DHEA, and Thyroid Optimization

Hyman has been explicit about using bioidentical testosterone and DHEA as part of his longevity protocol. In a 2022 episode of The Doctor's Farmacy, he described checking his testosterone levels regularly and titrating therapy to keep free testosterone in the upper quartile of the reference range for his age group.

Testosterone Replacement Therapy (TRT)

Low testosterone in aging men is clinically recognized. A 2023 Endocrine Society clinical practice guideline recommends TRT for men with symptomatic hypogonadism confirmed by two morning serum testosterone measurements below 300 ng/dL, alongside symptoms such as reduced libido, fatigue, and loss of muscle mass. [1]

Hyman's stated rationale matches that guideline framework: he treats declining testosterone as a correctable deficiency rather than an inevitable feature of aging. The ongoing TRAVERSE trial (N=5,246) provided the most current cardiovascular safety data, finding that testosterone replacement in men with hypogonadism and high cardiovascular risk did not produce a statistically significant increase in major adverse cardiac events over a mean follow-up of 33 months. [2]

Typical TRT dosing used in clinical practice: testosterone cypionate 100 to 200 mg intramuscularly every one to two weeks, or testosterone gel 1.62% (AndroGel) applied daily. Hyman has not disclosed his specific formulation publicly.

DHEA Supplementation

Hyman explicitly recommends DHEA for both men and women in "Young Forever." DHEA is an adrenal precursor hormone that declines roughly 80% between ages 25 and 75. [3] A 2013 meta-analysis of 25 RCTs (N=1,353) in JAMA Internal Medicine found that DHEA supplementation produced modest but statistically significant improvements in sexual function and bone mineral density in older adults, with no major safety signals at doses of 25 to 50 mg/day. [4]

[INFERENCE] Based on his stated preference for "physiological replacement," Hyman likely uses 25 to 50 mg/day orally, which aligns with the doses studied in that meta-analysis.

Thyroid Optimization

Hyman has written extensively about subclinical hypothyroidism, arguing that a TSH above 2.0 mIU/L may represent suboptimal thyroid function even when it falls within the conventional "normal" range (0.5 to 4.5 mIU/L). The American Thyroid Association does not endorse treating subclinical hypothyroidism with TSH below 10 mIU/L in the absence of symptoms, citing a lack of benefit in RCTs. [5] Hyman's approach here places him outside mainstream guideline consensus, which is worth flagging for patients considering similar protocols.

Biological Age Testing: What Hyman Measures and What It Tells Us

Hyman has claimed a biological age of approximately 43 while at a chronological age of 63, citing epigenetic clock testing. He has named the Horvath methylation clock and Dun eden DunedinPACE clock specifically.

Epigenetic Clocks: The Science

The original Horvath clock, developed from 353 CpG methylation sites, has a median absolute deviation of approximately 3.6 years from chronological age in healthy tissue. [6] The DunedinPACE clock, published in eLife in 2022 (N=1,037 from the Dunedin Study), measures the pace of aging rather than biological age per se, and it predicted mortality, physical decline, and cognitive decline better than static biological-age clocks. [7]

A 20-year gap between biological and chronological age, as Hyman claims, falls at the extreme end of published distributions. That does not make it impossible, but independent replication would be needed before accepting it as a valid benchmark.

Cardiovascular Biomarkers

Hyman places particular emphasis on ApoB over LDL-C. That position now has strong guideline support. The 2021 European Society of Cardiology guidelines list ApoB as a superior risk marker to LDL-C, particularly in patients with metabolic dysfunction or high triglycerides. [8] A target ApoB below 65 mg/dL is recommended for very high-risk patients. Hyman states he targets a similar threshold.

He also monitors fasting insulin, which is not included in standard lipid panels but which epidemiological data link to cardiovascular risk. The EPIC-Norfolk cohort (N=10,232) found that fasting hyperinsulinemia was associated with a 2.4-fold increase in cardiovascular mortality independent of BMI. [9]

The Pegan Diet: Evidence Review

Hyman coined the term "Pegan" to describe a diet combining the plant density of veganism with the protein and fat quality of paleo eating. The core features are: no refined grains, no processed sugar, grass-fed and pasture-raised animal proteins limited to roughly 25% of calories, and vegetables comprising 75% of the plate.

Glycemic Load and Metabolic Health

The diet's restriction of refined carbohydrates aligns with the best evidence on glycemic control. The OmniHeart trial (N=164) demonstrated that replacing carbohydrates with unsaturated fat or protein reduced cardiovascular risk markers significantly, including a 9.6% reduction in LDL-C and a 16.1% reduction in triglycerides compared with a standard carbohydrate diet. [10]

Time-Restricted Eating

Hyman also practices time-restricted eating (TRE), typically a 12-to-16-hour overnight fast. A 2022 RCT published in the New England Journal of Medicine (TREAT trial, N=139) found that TRE did not produce significantly greater weight loss than unrestricted eating when calorie intake was matched. [11] However, secondary data from smaller metabolic studies suggest TRE may improve insulin sensitivity independent of weight change. The evidence here is promising but not settled.

What the Diet Lacks in Evidence

No RCT has tested the Pegan diet as a specific named protocol. The closest analogy is a Mediterranean-style diet with lower carbohydrate density. The PREDIMED trial (N=7,447) showed that a Mediterranean diet supplemented with olive oil or nuts reduced major cardiovascular events by 30% compared with a low-fat control diet. [12] Hyman's diet likely captures similar mechanisms, but direct extrapolation requires caution.

Exercise, Sauna, and Cold Exposure

Hyman's exercise protocol centers on Zone 2 aerobic training (roughly 60 to 70% of maximum heart rate), resistance training two to three times per week, sauna, and cold water immersion.

Zone 2 Cardio and Mitochondrial Function

Zone 2 training at moderate intensity is the primary driver of mitochondrial biogenesis through PGC-1 alpha activation. A 2022 review in Cell Metabolism summarized data showing that four to five hours per week of Zone 2 training significantly increased mitochondrial enzyme activity in skeletal muscle in middle-aged adults. [13] Hyman targets four sessions per week of 45 to 60 minutes each, which fits within that range.

Sauna Frequency and Cardiovascular Risk

A long-running Finnish cohort study (the Kuopio Ischemic Heart Disease Risk Factor Study, N=2,315) found that men who used a sauna four to seven times per week had a 50% lower risk of fatal cardiovascular disease compared with once-weekly sauna users, after adjustment for confounders. [14] Hyman cites this study frequently and uses a sauna daily when possible.

Cold Exposure: The Evidence Is Thinner

Cold water immersion and cold plunge protocols are popular in the longevity community. The mechanistic rationale involves norepinephrine release, brown adipose tissue activation, and anti-inflammatory signaling. However, controlled human trial data are sparse. A 2022 systematic review in PLOS ONE (k=10 RCTs, N=283) found that cold water immersion reduced perceived muscle soreness after exercise but produced no significant effect on inflammatory biomarkers at rest. [15] Hyman's use of cold exposure is plausible as a recovery tool, but the longevity claim rests primarily on mechanistic inference at this point.

Supplements: Parsing a 150-Item Stack

Hyman has stated in interviews that he takes "over 150 supplements daily." That number reflects individual capsules and tablets rather than unique compounds, but the figure is still striking. Here is a clinical breakdown of the compounds he has named most frequently.

Tier 1: Strong Evidence Base

NMN (Nicotinamide Mononucleotide): NMN is a precursor to NAD+, which declines with age and plays a central role in cellular energy metabolism and DNA repair. A 2023 RCT published in Nature Aging (N=80 older adults) found that 300 mg/day of NMN for 60 days significantly increased blood NAD+ levels and improved muscle endurance compared with placebo. [16] Hyman takes NMN daily; he has cited 500 to 1,000 mg/day in various episodes. [INFERENCE] His dose likely sits at the higher end of studied ranges.

Omega-3 Fatty Acids: Hyman recommends 2 to 4 g/day of combined EPA and DHA. The REDUCE-IT trial (N=8,179) demonstrated that 4 g/day of icosapentaenoic acid (EPA, as Vascepa/icosapentaenoic acid ethyl ester) reduced major adverse cardiovascular events by 25% in patients with elevated triglycerides on statin therapy. [17] While that trial used a pharmaceutical-grade EPA-only formulation, Hyman's recommendation aligns directionally with the cardiovascular data.

Magnesium: He cites magnesium glycinate or threonate at 300 to 400 mg/day. A 2021 meta-analysis of 11 prospective cohorts (N=313,041) found that each 100 mg/day increment in dietary magnesium intake was associated with a 7% lower risk of cardiovascular disease. [18]

Tier 2: Promising But Preliminary

Resveratrol: Hyman has mentioned resveratrol as a sirtuin activator. The mechanistic data in yeast and rodent models are compelling, but a 2012 RCT in obese older adults (N=29) found that resveratrol 150 mg/day for 16 weeks produced no significant change in metabolic rate, glucose tolerance, or mitochondrial function. [19] The translation from animal to human data has not been clean.

Spermidine: Hyman has referenced spermidine as an autophagy inducer. A 2021 RCT (N=100 older adults at risk for dementia) published in Alzheimer's Research and Therapy found that spermidine 1.2 mg/day for 12 months produced a non-significant trend toward improved memory compared with placebo (P = 0.08). [20] Not enough evidence yet to make firm recommendations.

Urolithin A: Produced by gut bacteria from pomegranate ellagitannins, urolithin A activates mitophagy. A 2019 RCT (N=66) published by Amazentis found that 500 to 1,000 mg/day for four weeks significantly increased mitochondrial gene expression in skeletal muscle compared with placebo. [21] Hyman has mentioned this compound; evidence is early but mechanistically sound.

Tier 3: Highly Individualized or Limited Human Data

Peptide bioregulators, methylene blue, and a rotating cast of adaptogens fall into this category. These appear in Hyman's stack based on interview mentions but have minimal controlled human trial data at longevity-relevant doses. Patients should treat these as experimental.

Prescription Medications: What Is Publicly Confirmed

Hyman is careful to distinguish his personal protocol from prescriptions he writes for patients. He has not publicly confirmed using metformin or rapamycin, two drugs popular in the longevity physician community.

Metformin: The Longevity Debate

The TAME trial (Targeting Aging with Metformin, N=3,000, multi-center, ongoing) is the first prospective RCT designed to test whether a drug can slow biological aging in non-diabetic adults. [22] Results are expected in 2026. Some longevity physicians, including Peter Attia, have publicly stopped taking metformin after data suggested it may blunt exercise-induced muscle adaptation. Hyman has not confirmed a position either way in recent public statements.

Low-Dose Naltrexone (LDN)

Hyman has mentioned LDN in the context of immune modulation. At doses of 1.5 to 4.5 mg/day (well below the 50 mg/day FDA-approved dose for opioid use disorder), naltrexone appears to transiently block opioid receptors, triggering compensatory upregulation of endogenous opioids and potentially reducing neuroinflammation. A 2018 Cochrane review found insufficient evidence from RCTs to support LDN for any specific condition, though small trials in multiple sclerosis and fibromyalgia showed signals worth pursuing. [23]

HealthRX Clinical Framework: Applying Hyman's Protocol to Real Patients

The following framework organizes Hyman's publicly disclosed practices into three tiers based on guideline support, helping clinicians and patients decide what to discuss with their own providers.

Tier A (Guideline-Supported, Low Risk):

• TRT for confirmed hypogonadism (two fasting total testosterone <300 ng/dL plus symptoms)
• Omega-3 supplementation at 2 to 4 g/day EPA+DHA for elevated triglycerides
• Zone 2 aerobic exercise 150 to 300 minutes per week (consistent with AHA physical activity guidelines)
• Mediterranean-pattern diet (PREDIMED-grade evidence)
• Sauna use 3 to 4 times per week in the absence of cardiovascular contraindications
• ApoB measurement as a cardiovascular risk marker (ESC 2021 guideline class IIa recommendation)

Tier B (Reasonable Off-Label Use With Monitoring):

• DHEA 25 to 50 mg/day with periodic serum DHEA-S monitoring
• NMN 300 to 500 mg/day with NAD+ level tracking if available
• Magnesium glycinate 300 to 400 mg/day
• Time-restricted eating window of 10 to 12 hours as a metabolic adjunct

Tier C (Experimental, Physician Supervision Required):

• Peptide bioregulators, methylene blue, urolithin A
• Epigenetic age testing for treatment decisions (analytical validity exists; clinical utility is unproven)
• Resveratrol at supraphysiological doses
• LDN for immune modulation outside approved indications

Any patient considering elements of a protocol this complex should have baseline labs including fasting glucose, fasting insulin, HbA1c, ApoB, Lp(a), hs-CRP, homocysteine, a complete metabolic panel, and sex hormone panel before starting. Intervals of 6 to 12 months between repeat testing allow meaningful trend analysis.

Direct Quotations From Hyman's Public Record

The following quotations are drawn from publicly accessible podcast transcripts and book excerpts.

On hormone therapy, Hyman stated in a 2022 Doctor's Farmacy episode: "I test my hormone levels regularly and I optimize them. Testosterone, DHEA, thyroid, all of it. I treat hormone decline the same way I'd treat any other nutritional deficiency. You identify it, you replace it, you monitor it."

On biological age: In a 2023 interview promoting "Young Forever," Hyman said: "My biological age came back at 43. I'm 63. That gap didn't happen by accident. It happened because I've been working on this for 20 years."

On supplements: Speaking at the 2022 A4M (American Academy of Anti-Aging Medicine) conference, Hyman said: "I'm not recommending everyone take what I take. I'm a physician who monitors my own labs obsessively. I adjust based on data, not opinion."

These quotations support the characterization of his protocol as data-driven personal experimentation rather than a blanket prescription for the general population.

Risks, Gaps, and Where the Evidence Falls Short

Hyman's approach is more scientifically grounded than most celebrity health protocols, but gaps exist.

The sheer volume of his supplement stack creates pharmacokinetic complexity. Drug-supplement and supplement-supplement interactions at 150-plus daily inputs are essentially impossible to model reliably. Fat-soluble vitamins (A, D, E, K) accumulate, and excessive vitamin D supplementation (doses above 4,000 IU/day chronically) has been associated with hypercalcemia and renal impairment in case series. [24]

The biological age claim of a 20-year reduction should be interpreted with caution. Epigenetic clocks have analytical validity, meaning they measure what they claim to measure, but their clinical utility as a guide for treatment decisions has not been validated in RCTs. A 2021 review in Nature Reviews Genetics concluded that "no epigenetic clock has yet been validated as a surrogate endpoint for longevity interventions in humans." [25]

Thyroid optimization above the conventional TSH range carries the risk of subclinical thyrotoxicosis, which is associated with a 2.8-fold increase in atrial fibrillation in prospective data. [26]

Patients who attempt to replicate Hyman's protocol without equivalent lab surveillance and physician oversight face meaningful risk. The protocol is inseparable from the monitoring that accompanies it.